Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PF-03463275
- Development stage
- Phase 2
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
PF-03463275 is a centrally penetrant, orally available small molecule that acts as a selective and competitive inhibitor of glycine transporter 1 (GlyT1), also known as solute carrier family 6 member 9 (SLC6A9). By inhibiting GlyT1, it increases extracellular glycine levels in the synaptic cleft and is hypothesized to potentiate N-methyl-D-aspartate receptor (NMDAR) transmission through coagonist stimulation. This mechanism was investigated for its potential to treat cognitive impairments associated with schizophrenia. The drug demonstrated improvement in working memory accuracy in patients with schizophrenia but did not show significant benefit for cognitive impairment when combined with cognitive training compared to placebo. Clinical development reached phase II trials before being discontinued. The drug was developed by Pfizer[1][2][3][4][5][6][7].
- Other names
- compound 10compound10compound-10KB-79869KB79869KB 79869
02
Targets
SLC6A9 (Glycine transporter type 1)
Beyond the preview
Go deeper on PF-03463275.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PF-03463275.